Immuron is an Australian biopharmaceutical company that develops and sells orally delivered polyclonal antibody therapies targeting gastrointestinal infections and diseases. The company's primary commercial product is Travelan, an over-the-counter product derived from bovine colostrum that reduces the risk of travelers' diarrhea. Immuron sells Travelan to travelers and military personnel through retail pharmacies, grocery channels, travel clinics, and online retailers across Australia, the U.S., and Canada. Immuron also sells ProIBS, an over-the-counter product for irritable bowel syndrome symptoms in Australia. Immuron manufactures Travelan from hyper-immune bovine colostrum sourced through dairy industry suppliers. The company funds operations through commercial product sales and research grants while outsourcing clinical trial execution to academic and government institutions. Immuron's strategy centers on advancing its clinical pipeline, including seeking FDA prescription approval for Travelan via a Biologics License Application and developing IMM-529 for Clostridioides difficile infections.